View Older Stories View More Recent Stories
-
JPMorgan Reiterates Overweight Rating on Abbott Labs (ABT)
-
Abbott (ABT) Tops Q1 EPS by 2c, Offers Guidance
-
Abbott (ABT) call put ratio 1.1 calls to 1 put into quarter results
-
Abbott (ABT) call put ratio 2.8 calls to 1 put into quarter results
-
Stifel Reiterates Buy Rating on Abbott Labs (ABT)
-
TD Cowen Reiterates Buy Rating on Abbott Labs (ABT), Expecting 'Good Quarterly Results'
-
Oppenheimer Reiterates Outperform Rating on Abbott Labs (ABT)
-
Piper Sandler Conducts a Survey: 'Abbott Labs (ABT) Biggest Share Gainer'
-
RBC Capital Assesses U.S. Tariff Impact Across Industries
-
Oppenheimer Reiterates Outperform Rating on Abbott Labs (ABT) Following CE Mark news
-
BTIG Reiterates Buy Rating on Abbott Labs (ABT)
-
Abbott (ABT) Receives CE Mark for its Volt Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms
-
Abbott (ABT) initiates new trail for Coronary IVL System
-
TD Cowen Reiterates Buy Rating on Abbott Labs (ABT)
-
Abbott (ABT) call put ratio 1.2 calls to 1 put amid price movement
-
RFK Jr. Said To Meet With Baby Formula Manufacturers - Bloomberg
-
BofA Securities on Abbott Labs (ABT): 'durable revenue growth at the high end of medtech and double-digit EPS growth'
-
Citi on Abbott Labs (ABT): 'we view the overturned state case as incrementally negative'
-
RBC Capital: 'Opportunities Across MedTech Stocks'
-
Jefferies Reiterates Hold Rating on Edwards Lifesciences (EW)
-
Cadrenal Therapeutics (CVKD) Announces Collaboration Agreement with Abbott (ABT) in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3 LVAD
-
Abbott (ABT) Declares $0.59 Quarterly Dividend; 1.8% Yield
-
IVF stocks on watch as President Trump signs an executive order to expand access
-
KeyBanc Highlights WST, GXIG, and STVN as GLP-1 Estimates Raise
-
Abbott Labs (ABT) PT Raised to $158 at Barclays
-
Abbott Labs (ABT) PT Raised to $138 at Bernstein, Citing 'Strong Momentum'
-
Abbott Labs (ABT) PT Raised to $148 at UBS
-
Abbott Labs (ABT) PT Raised to $135 at Stifel
-
Abbott Labs (ABT) PT Raised to $140 at BTIG
-
Abbott Labs (ABT) PT Raised to $140 at BTIG
-
Abbott (ABT) Reports In-Line Q4 EPS; offers guidance
-
Abbott (ABT) call put ratio 3.4 calls to 1 put with a focus on January 31 weekly 121 calls into quarter results
-
US To Ban Red Dye No. 3 In Food As Soon As Wednesday: Sources - Bloomberg
-
Abbott Labs (ABT) PT Raised to $135 at TD Cowen
-
RBC's Best Picks For 2025 in Medical Supplies & Devices: 'Oasis of Opportunity Awaits as MedTech Momentum Continues'
-
Abbott (ABT) Declares $0.59 Quarterly Dividend; 2.1% Yield
-
RBC comments on medical devices sector ahead of EW's Investor Day
-
Is Trump 2.0 good or bad for healthcare stocks?
-
Barclays highlights most and least sensitive MedTech stocks to changes in surgical volumes
-
Abbott Labs (ABT) PT Raised to $149 at Barclays
-
Abbott (ABT), Reckitt Unit Defeat Infant-formula Sickness Claims - Bloomberg
-
Abbott and the Big Ten Conference Tackle U.S. Blood Shortages With First-of-Its-Kind, Nationwide Blood Donation Competition, 'The We Give Blood Drive'
-
Abbott Labs (ABT) PT Raised to $133 at Piper Sandler
-
Oppenheimer Reiterates Outperform Rating on Abbott Labs (ABT)
-
TD Cowen Reiterates Buy Rating on Abbott Labs (ABT)
-
JPMorgan Reiterates Overweight Rating on Abbott Labs (ABT)
-
Abbott Labs (ABT) PT Raised to $125 at Jefferies
-
Abbott Labs (ABT) PT Raised to $130 at Stifel
-
Abbott Labs (ABT) PT Raised to $128 at Evercore ISI
-
Abbott Labs (ABT) PT Raised to $139 at BTIG

